Bioventus (NASDAQ:BVS) Issues FY 2026 Earnings Guidance

Bioventus (NASDAQ:BVS) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.750-0.790 for the period, compared to the consensus EPS estimate of 0.770. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $605.1 million.

Bioventus Stock Performance

Shares of Bioventus stock traded down $1.42 on Thursday, reaching $13.84. The stock had a trading volume of 1,154,475 shares, compared to its average volume of 526,768. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The business’s 50-day moving average price is $10.59 and its two-hundred day moving average price is $9.61. The stock has a market cap of $1.16 billion, a P/E ratio of 33.78, a price-to-earnings-growth ratio of 1.71 and a beta of 0.63. Bioventus has a fifty-two week low of $6.26 and a fifty-two week high of $15.89.

Bioventus (NASDAQ:BVS) last announced its earnings results on Wednesday, August 5th. The company reported $0.22 EPS for the quarter, hitting the consensus estimate of $0.22. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. The firm had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts forecast that Bioventus will post 0.79 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of Bioventus in a report on Tuesday, June 16th. Barrington Research set a $18.00 price objective on shares of Bioventus in a report on Thursday. Finally, Craig Hallum reaffirmed a “buy” rating and set a $18.00 price objective on shares of Bioventus in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $16.25.

Trending Headlines about Bioventus

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Bioventus reported second-quarter revenue of $153.2 million, up 4% year over year, while adjusted EPS rose to $0.22 from $0.21 and met consensus estimates. Pain Treatments led growth, with revenue increasing 11.5%, driven by strong Durolane volume. Bioventus Fiscal Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Reaffirmed
• Positive Sentiment: GAAP diluted EPS increased to $0.47 from $0.11, and net income attributable to Bioventus rose to $33.4 million from $7.5 million. However, the improvement was aided partly by the removal of a $24.6 million deferred-tax valuation allowance. Cash from operations totaled $19.9 million. Bioventus Reports Second Quarter Financial Results
• Positive Sentiment: Management reaffirmed 2026 guidance for revenue of $600 million to $610 million, adjusted EPS of $0.75 to $0.79 and operating cash flow of $84 million to $89 million. The company also made a $20 million term-loan prepayment, potentially reducing interest costs and leverage. Bioventus outlines 2026 net leverage below 1.5x while board reviews strategic options
• Positive Sentiment: The board launched a review of strategic alternatives after receiving an unsolicited acquisition proposal and other expressions of interest. A potential sale could create takeover interest and support shareholder value, although no transaction is assured. $600M Durham company weighs sale as stock soars

Hedge Funds Weigh In On Bioventus

A number of hedge funds have recently modified their holdings of BVS. Marshall Wace LLP raised its holdings in shares of Bioventus by 0.4% in the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock valued at $2,149,000 after buying an additional 1,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after purchasing an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its position in shares of Bioventus by 16.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after buying an additional 1,887 shares during the period. Deutsche Bank AG grew its position in shares of Bioventus by 8.2% during the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after buying an additional 1,908 shares during the period. Finally, Engineers Gate Manager LP grew its position in shares of Bioventus by 6.0% during the 4th quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after buying an additional 3,909 shares during the period. 62.94% of the stock is owned by institutional investors and hedge funds.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.